Literature DB >> 10819335

Twice weekly vs. daily chemotherapy for childhood tuberculosis.

J M Te Water Naude1, P R Donald, G D Hussey, M A Kibel, A Louw, D R Perkins, H S Schaaf.   

Abstract

BACKGROUND: Treating childhood tuberculosis places a large burden on health services, and ways of lessening this were sought.
METHODS: A randomized controlled trial was conducted to determine the effectiveness of fully intermittent twice weekly treatment for intrathoracic childhood tuberculosis and its effect on adherence to treatment, in comparison with daily (weekday) treatment. The setting was a district of Cape Town, South Africa, an area of high incident tuberculosis. We randomized 206 children with confirmed (4%), probable (94%) and suspected (2%) intrathoracic tuberculosis: 89 (median age, 25 months) received intermittent treatment; and 117 (median age, 28 months) received daily treatment. Intermittent treatment (twice weekly for 6 months) was isoniazid 15 mg/kg/dose, rifampin 15 mg/kg/dose and pyrazinamide 55 mg/kg/dose for 2 months, followed by isoniazid and rifampin only for 4 months. Daily treatment was isoniazid 10 mg/kg/day, rifampin 10 mg/kg/day and pyrazinamide 25 mg/kg/day on weekdays for 6 months.
RESULTS: At 6 months 97% of subjects were discharged, with treatment outcomes in the two groups equivalent at that time (P = 0.90) and at the 18- to 30-month follow-up. One relapse occurred in the twice weekly group (P = 0.25). Adherence was equivalent; 70 children (79%) on intermittent and 90 (77%) on daily treatment took 75% or more of the prescribed doses (P = 0.90). Nonadherence over the full course of therapy was significantly associated with nonadherence during the first month of treatment (P = 0.0002) and household crowding (P = 0.002).
CONCLUSIONS: Six month fully intermittent antituberculosis treatment is an effective and acceptable alternative to daily treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819335     DOI: 10.1097/00006454-200005000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

Review 1.  Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.

Authors:  Chrysanthi L Skevaki; Dimitrios A Kafetzis
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 3.  Treatment of childhood tuberculosis.

Authors:  D Vijayasekaran
Journal:  Indian J Pediatr       Date:  2010-10-29       Impact factor: 1.967

Review 4.  Tuberculosis (HIV-negative people).

Authors:  Lilia E Ziganshina; Michael Eisenhut
Journal:  BMJ Clin Evid       Date:  2011-03-11

Review 5.  Newer diagnostic modalities for tuberculosis.

Authors:  Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

Review 6.  Tuberculosis (HIV-negative people).

Authors:  Lilia E Ziganshina; Paul Garner
Journal:  BMJ Clin Evid       Date:  2009-04-14

7.  Antituberculosis drug-induced hepatotoxicity in children.

Authors:  Peter R Donald
Journal:  Pediatr Rep       Date:  2011-06-16

8.  Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules.

Authors:  Stanzi M le Roux; Mark F Cotton; Jonathan E Golub; David M le Roux; Lesley Workman; Heather J Zar
Journal:  BMC Med       Date:  2009-11-03       Impact factor: 8.775

9.  Transparent reporting of recruitment and informed consent approaches in clinical trials recruiting children with minor parents in sub-Saharan Africa: a secondary analysis based on a systematic review.

Authors:  Angela De Pretto-Lazarova; Domnita Oana Brancati-Badarau; Christian Burri
Journal:  BMC Public Health       Date:  2021-07-28       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.